CÁNCER DE MAMA
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublikationen in Zusammenarbeit mit Forschern von GlaxoSmithKline (United Kingdom) (3)
2024
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
-
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Clinical Therapeutics
2013
-
Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients
Clinical Pharmacology in Drug Development, Vol. 2, Núm. 4, pp. 336-341